Gelesis (NYSE:GLS) Trading Up 0.4%
Gelesis (NYSE:GLS) Trading Up 0.4%
(Get Rating) Gelesis Holdings, Inc. (NYSE:GLS – Get Rating)'s share price was up 0.4% during trading on Monday . The stock traded as high as $0.16 and last traded at $0.16. Approximately 185,100 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 386,034 shares. The stock had previously closed at $0.16.
Gelesis Holdings, Inc.（紐約證券交易所代碼：GLS — 獲取評級）的股價在週一的交易中上漲了0.4％。該股交易價格高達0.16美元，最後一次交易價格爲0.16美元。午盤交易中約有185,100股交易，較平均每日交易量386,034股下降了52％。該股此前收於0.16美元。
Gelesis Trading Up 0.4 %
蓋萊西斯交易量上漲0.4％
The company has a market capitalization of $11.63 million, a PE ratio of -0.11 and a beta of 0.88. The business's 50-day simple moving average is $0.23 and its 200-day simple moving average is $0.40.
該公司的市值爲1163萬美元，市盈率爲-0.11，beta值爲0.88。該公司的50天簡單移動平均線爲0.23美元，其200天簡單移動平均線爲0.40美元。
Institutional Investors Weigh In On Gelesis
機構投資者權衡格萊西斯
Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp acquired a new stake in shares of Gelesis during the 1st quarter worth approximately $250,000. Northern Trust Corp acquired a new stake in Gelesis in the 1st quarter valued at $180,000. Goldman Sachs Group Inc. acquired a new stake in Gelesis in the 1st quarter valued at $103,000. Charles Schwab Investment Management Inc. acquired a new stake in Gelesis in the 1st quarter valued at $76,000. Finally, Virtu Financial LLC acquired a new stake in Gelesis in the 1st quarter valued at $73,000. Institutional investors and hedge funds own 16.71% of the company's stock.
對沖基金和其他機構投資者最近改變了他們在公司的頭寸。State Street Corp在第一季度收購了Gelesis的新股份，價值約25萬美元。北方信託公司在第一季度收購了Gelesis的新股份，價值18萬美元。高盛集團公司在第一季度收購了Gelesis的新股份，價值10.3萬美元。查爾斯·施瓦布投資管理公司在第一季度收購了Gelesis的新股份，價值76,000美元。最後，Virtu Financial LLC在第一季度收購了價值73,000美元的Gelesis的新股份。機構投資者和對沖基金擁有該公司16.71％的股票。
About Gelesis
關於 Gelesis
(Get Rating)
（獲取評分）
Gelesis Holdings Inc, a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.
Gelesis Holdings Inc是一家處於商業階段的生物療法公司，正在開發一種用於治療肥胖和胃腸道相關慢性病的起因的生物仿生物。該公司還提供 PLENITY，這是一種用於體重管理的口服、非興奮劑和非全身性輔助藥物。此外，它還提供針對肥胖和超重的產品，以及非酒精性脂肪肝疾病/非酒精性脂肪性肝炎、2 型糖尿病和功能性便祕的 GS500 的潛在療法在研產品線。
Featured Stories
精選故事
- Get a free copy of the StockNews.com research report on Gelesis (GLS)
- Medtronic: Reversal In-Play For This High-Yield Stock
- Is it 'Game Over' for Roblox After Reporting March Metrics Miss?
- Is it Time to Take Profits in Chip Stocks?
- Will Stratasys Continue to be a Runaway Bride?
- Garrett Motion Inc. Skids on Results: Is it Time to Buy the Dip?
- 免費獲取 StockNews.com 關於 Gelesis（GLS）的研究報告的副本
- 美敦力：這隻高收益股票的反轉正在進行中
- 在報告三月份的指標失誤後，Roblox 的 “遊戲結束了” 嗎？
- 是時候在芯片股中獲利了嗎？
- Stratasys 會繼續成爲逃跑的新娘嗎？
- Garrett Motion Inc. 對業績持懷疑態度：是時候逢低買入了嗎？
Receive News & Ratings for Gelesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelesis and related companies with MarketBeat.com's FREE daily email newsletter.
接收《蓋萊西斯日報》的新聞和收視率 -在下面輸入您的電子郵件地址，以通過Marketbeat.com的免費每日電子郵件時事通訊接收有關Gelesis及相關公司最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。
